Mesa Nilda, director in United Therapeutics Corp (NASDAQ: ), a biopharmaceutical company with impressive gross profit margins of 89% and an “Excellent” rating InvestingPro financial health rating, she sold shares of the company’s common stock, according to a recent filing with the SEC. The transaction dated December 30, 2024 involved the sale of 255 shares at an average price of $355.77 each, for a total of approximately $90,720. After this sale, Nilda’s direct ownership is 5,528 shares. The stock has shown remarkable stability with a beta of 0.55 and has delivered a strong return of 62.6% year-to-date. For deeper insight into insider transactions and 13 additional key metrics, explore the comprehensive Pro Research Report available at InvestingPro.
In other recent news, United Therapeutics Corporation is making waves with a significant development. The company recently announced the successful transplantation of a genetically engineered pig kidney into a human patient, marking a major milestone in the field of xenotransplantation. This innovative procedure, which is being conducted under the FDA’s expanded access pathway, could potentially offer a solution to the organ shortage.
At the same time, United Therapeutics is making strides in the financial area. The company reported strong financial results in the third quarter, with revenues reaching $748.9 million, primarily driven by strong results from its treprostinil-based products. However, not all products met the projections, and the sales of Remodulin are slightly below expectations.
The company’s financial performance has attracted the attention of analysts. HC Wainwright reaffirmed a Buy rating on the company and raised its price target to $425, citing strategic positioning and proactive measures. In contrast, Ladenburg Thalmann maintained its Neutral rating but raised its price target to $344.
In addition to this development, United Therapeutics completed a $1 billion accelerated share repurchase program. The company is also preparing for future clinical milestones, including the results of the TETON 2 study, and is awaiting a potential FDA decision on its Centralized Lung Assessment System in 2025. These recent developments underscore United Therapeutics’ strategic focus on expanding commercial ventures and research and development.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
